CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.
Eur Neuropsychopharmacol
; 2(1): 31-5, 1992 Mar.
Article
en En
| MEDLINE
| ID: mdl-1638171
ABSTRACT
Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebo. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Circulación Cerebrovascular
/
Cognición
/
Enfermedad de Alzheimer
/
Inhibidores de la Monoaminooxidasa
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Año:
1992
Tipo del documento:
Article